Ascletis Pharma (HKG:1672) said it has dosed the first patients in its US clinical study for the combination of ASC47 and semaglutide for weight loss patients who do not have type 2 diabetes.
ASC47 is indicated for obese patients and adipose tissue or body fat, according to a Tuesday filing with the Hong Kong bourse.
The drug reduced body weight by about 57% and preserved muscles in diet-induced obese mouse models, the filing said.